Global Glycerol Phenylbutyrate Market Size By Type (25ml, 50ml), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Glycerol Phenylbutyrate Market was valued at USD 380 million in 2023 and is projected to reach USD 642 million by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031. Glycerol phenylbutyrate, a prodrug of phenylbutyric acid, is primarily used in the treatment of urea cycle disorders (UCDs) by reducing ammonia levels in patients. The increasing awareness of rare metabolic disorders, rising global healthcare expenditures, and enhanced diagnostic capabilities are propelling the demand for this therapeutic compound. Moreover, the drug's growing use in managing hepatic encephalopathy is opening new avenues for market expansion.

Drivers:

Increasing Prevalence of Urea Cycle Disorders:

As more cases of urea cycle disorders are diagnosed, especially in neonates and children, the demand for glycerol phenylbutyrate is growing. Improved awareness and screening programs globally are contributing to early detection and subsequent therapeutic intervention.

Advancements in Rare Disease Treatment:

Governments and pharmaceutical companies are investing significantly in orphan drug development. Glycerol phenylbutyrate has been granted orphan drug status in several markets, accelerating research, funding, and market entry.

Expansion of Healthcare Infrastructure:

Emerging markets are witnessing considerable improvements in healthcare access, leading to increased diagnosis and treatment of metabolic disorders. This trend supports the adoption of novel therapies such as glycerol phenylbutyrate.

Restraints:

High Cost of Treatment:

The therapy is expensive, especially in markets where insurance coverage is limited. This restricts accessibility and slows adoption in low- and middle-income countries.

Limited Awareness in Underdeveloped Regions:

Many regions lack adequate knowledge and diagnostic tools for rare genetic disorders. This limits early diagnosis and reduces the potential patient base for glycerol phenylbutyrate.

Opportunity:

Expansion Beyond UCDs:

Ongoing clinical trials and off-label usage suggest potential applications in treating hepatic encephalopathy and other hyperammonemia-related conditions. These new indications offer significant market expansion opportunities.

Strategic Collaborations and Licensing:

Collaborations between biotech firms and research institutions are paving the way for enhanced drug formulations and global reach. Partnerships focusing on improving drug delivery mechanisms and regional penetration are expected to drive future growth.

Market by System Type Insights:

The market is segmented by dosage forms into oral liquid and tablet/capsule formulations. The oral liquid segment dominated the market in 2023 due to its suitability for pediatric and geriatric patients. However, capsule formulations are gaining traction for adult patients seeking convenience and improved compliance. Innovations in taste-masking and controlled-release technologies are further bolstering this segment's growth.

Market by End-use Insights:

In terms of end-use, hospitals accounted for the largest share in 2023, driven by the prevalence of in-patient treatments for acute hyperammonemia. Specialty clinics and home care settings are expected to register the fastest growth due to a shift toward outpatient treatment models, especially in developed regions where home-based metabolic monitoring is becoming viable.

Market by Regional Insights:

North America held the largest market share in 2023, supported by strong awareness, favorable reimbursement policies, and the presence of key pharmaceutical companies. Europe followed, with substantial investments in rare disease research and patient registries. Asia-Pacific is projected to witness the fastest growth due to rising healthcare infrastructure and government initiatives supporting rare disease management, particularly in China, Japan, and India.

Competitive Scenario:

Key players in the Global Glycerol Phenylbutyrate Market include:

Horizon Therapeutics plc

Recordati Rare Diseases Inc.

Acer Therapeutics

Ultragenyx Pharmaceutical Inc.

Exela Pharma Sciences

These companies are focused on securing regulatory approvals, investing in expanded indication research, and improving global distribution networks. For instance:

In 2024, Horizon Therapeutics expanded its clinical trials for glycerol phenylbutyrate into Asia, targeting hepatic encephalopathy patients.

In 2023, Acer Therapeutics partnered with a European biotech firm to co-develop an extended-release version of the drug aimed at reducing dosing frequency.

In 2022, Recordati Rare Diseases launched an awareness campaign across Latin America, increasing regional adoption.

Scope of Work – Global Glycerol Phenylbutyrate Market

Report Metric Details

Market Size (2023) USD 380 million

Projected Market Size (2031) USD 642 million

CAGR (2023–2031) 6.8%

Market Segments By Dosage Form (Oral Liquid, Capsules), By End-use (Hospitals, Clinics, Homecare)

Growth Drivers Rising prevalence of urea cycle disorders, orphan drug designation, increasing access to healthcare in emerging markets

Opportunities Expanded indications (hepatic encephalopathy), strategic collaborations, innovations in drug delivery

Key Market Developments:

April 2024: Horizon Therapeutics initiated Phase III trials for glycerol phenylbutyrate targeting hepatic encephalopathy.

December 2023: Acer Therapeutics secured EMA fast-track approval for expanded use of glycerol phenylbutyrate in adult hyperammonemia cases.

June 2023: Recordati Rare Diseases launched a digital campaign to improve awareness of urea cycle disorders and treatment options in Latin America.

FAQs:

What is the current market size of the Global Glycerol Phenylbutyrate Market?

The market was valued at USD 380 million in 2023.

What is the major growth driver of the Global Glycerol Phenylbutyrate Market?

The increasing prevalence of urea cycle disorders and orphan drug status are major drivers.

Which is the largest region during the forecast period in the Global Glycerol Phenylbutyrate Market?

North America holds the largest market share due to high awareness and reimbursement support.

Which segment accounted for the largest market share in the Global Glycerol Phenylbutyrate Market?

The oral liquid formulation segment accounted for the largest share in 2023.

Who are the key market players in the Global Glycerol Phenylbutyrate Market?

Key players include Horizon Therapeutics, Recordati Rare Diseases, Acer Therapeutics, Ultragenyx, and Exela Pharma Sciences.